Organophosphate Poisoning and Subsequent Acute Kidney Injury Risk
A Nationwide Population-Based Cohort Study

Feng-You Lee, MD, Wei-Kung Chen, MD, Cheng-Li Lin, MSc, Ching-Yuan Lai, MD, Yung-Shun Wu, MD, I-Ching Lin, MD, PhD, and Chia-Hung Kao, MD

Abstract: Small numbers of the papers have studied the association between organophosphate (OP) poisoning and the subsequent acute kidney injury (AKI). Therefore, we used the National Health Insurance Research Database (NHIRD) to study whether patients with OP poisoning are associated with a higher risk to have subsequent AKI.

The retrospective cohort study comprised patients aged ≥20 years with OP poisoning and hospitalized diagnosis during 2000–2011 (N = 8924). Each OP poisoning patient was frequency-matched to 4 control patients based on age, sex, index year, and comorbidities of diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, coronary artery disease, and stroke (N = 35,696). We conducted Cox proportional hazard regression analysis to estimate the effects of OP poisoning on AKI risk.

The overall incidence of AKI was higher in the patients with OP poisoning than in the controls (4.85 vs 3.47/1000 person-years). After adjustment for age, sex, comorbidity, and interaction terms, patients with OP poisoning were associated with a 6.17-fold higher risk of AKI compared with the comparison cohort. Patients with highly severe OP poisoning were associated with a substantially increased risk of AKI.

The study found OP poisoning is associated with increased risk of subsequent AKI. Future studies are encouraged to evaluate whether long-term effects exist and the best guideline to prevent the continuously impaired renal function.

(Medicine 94(47):e2107)

INTRODUCTION

For the last 60 years, organophosphate (OP) poisoning has been one of the most crucial public health concerns worldwide. According to the World Health Organization’s estimates, there are >3 million cases of OP pesticide poisoning annually; among these, >250,000 deaths are caused by intentional self-poisoning, accounting for 30% of suicides worldwide.1–3 OP pesticides are used to eliminate or control various pests, and most contact poisonings occur in the agricultural societies of developing countries where such toxic compounds are readily available.1 The mechanism of OP toxicity is the irreversible inhibition of the enzyme cholinesterase, leading to massive accumulation of the neurotransmitter acetylcholine within the synaptic cleft, and, thus, overstimulation of nicotinic and muscarinic receptors in the central and peripheral nervous system, which form various toxidromes.1,4–5 Even with adequate medical care in the setting of well-equipped intensive care units, the mortality rate could reach 40%, and respiratory failure represents the leading cause of death.1,6 Other toxicity-related complications include motor neuropathy, arrhythmia, pulmonary edema, pneumonia, pancreatitis, and renal failure.3,7,8

Acute kidney injury (AKI) is a worldwide concern with diverse etiologies and clinical presentations. Misidentifying or underestimating the problem may lead to severe adverse outcomes. According to the literature, critically ill patients who develop AKI are associated with high morbidity, resulting in long hospital stays, high medical expenditure, and a risk of long-term dialysis.3 However, few studies have investigated the correlation between OP poisoning and the subsequent risk of AKI. To obtain sufficient statistical power, we used a large-scale, nationwide database for analysis and sought to delineate...
the possible role of OP poisoning in the development of AKI in patients with no history of prior kidney disease.

**METHODS**

**Data Source**

The National Health Insurance (NHI) program was launched in Taiwan on March 1, 1995, and it consists of detailed healthcare data from >23 million enrollees, representing >99% of the population of Taiwan (http://www.nhi.gov.tw/english/index.aspx). The National Health Insurance Research Database (NHIRD) contains comprehensive information regarding clinical visits for each insured person, including the scrambled patient identification number, demographic characteristics, inpatient and outpatient dates, prescription details, and diagnostic codes based on the International Classification of Diseases, Ninth revision, Clinical Modification (ICD-9-CM). To protect the privacy of all the persons registered in the NHI program, the National Health Research Institutes encrypts and converts the identification numbers of all NHIRD records before releasing them for researchers. For this study, we used a subset of the NHIRD containing health care data including files of inpatient claims and the registry of beneficiaries. This study was exempted from informed consent by the institutional review board of China Medical University (CMUH-104-REC2-115).

**Sampled Patients**

Patients in the inpatient database with newly identified OP poisoning (ICD-9 code 989.3) from 2000–2011 were selected as the OP poisoning cohort. The date of the first admission for OP poisoning was used as the index date. For each patient with OP poisoning, we randomly selected 4 persons without OP poisoning from all NHI beneficiaries and frequency-matched them according to age (every 5-year span), sex, the year of index date, and comorbidities of diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), and stroke. The index date in non–OP poisoning controls was randomly assigned a date in OP poisoning cases. In both cohorts, patients who were diagnosed with AKI (ICD-9 code 584), chronic kidney disease (ICD-9 codes 580–589), or end-stage renal disease (ICD-9 code 585) before the index date, or who had missing information for age and sex, were excluded from the data analysis. Those patients with a history of AKI were also excluded from the study (Fig. 1).

**Outcome and Comorbidities**

The main outcome was hospitalization with a new diagnosis of AKI (ICD-9 code 584) during the follow-up. All the studied patients were followed from the index date to the occurrence of AKI, withdrawal from the database, or December 31, 2011.

We also incorporated an inpatient diagnosis file to ascertain the comorbidities including diabetes (ICD-9 code 250), hypertension (ICD-9 codes 401–405), hyperlipidemia (ICD-9 code 272), COPD (ICD-9 code 491, 492, and 496), congestive heart failure (CHF) (ICD-9 code 428), CAD (ICD-9 codes 410–414), and stroke (ICD-9 codes 430–438). In addition, acute respiratory failure (ICD-9-CM code 518.81), central venous pressure monitoring (ICD-9-OP code 8962), and mechanical ventilation (ICD-9-OP codes 9390 and 967) were considered as severity indicators based on diagnoses in the admission records within the first 3 days of hospitalization.

In the present study, we used ICD-9-CM code 989.3 (toxic effect of OP and carbamate) to identify patients with OP poisoning, which comprised our study cohort and separated from other types of poisoning (such as paraquat), which were classified and coded into another group (ICD-9-CM code 989.4). We also conducted an additional analysis to clarify the effect of other types of poisoning (ICD-9-CM code 989.4) on AKI.

![FIGURE 1. Derivation of our study cohort.](image-url)
Statistical Analysis

Distributions of age (≤34, 35–49, 50–64, and ≥65 years), sex, and comorbidities were compared between the OP poisoning and non–OP poisoning cohorts, and examined using the χ² test. The median ages and median follow-up years of both cohorts were measured and compared using the Mann–Whitney U test. The follow-up times were used to estimate the incidence density rates of AKI in both cohorts. Univariate and multivariable Cox proportional hazards regression models were used to examine the effect of OP poisoning on the risk of AKI development, as shown by hazard ratios (HRs) with 95% confidence intervals (CIs). The multivariable models simultaneously adjusted for age, sex, comorbidities of diabetes, hypertension, hyperlipidemia, COPD, CHF, CAD, and stroke, and multiplicative interactions of age and OP poisoning, diabetes and OP poisoning, CAD and OP poisoning, stroke and OP poisoning, diabetes and age, hypertension and age, coagulation and diabetes, stroke and diabetes, hypertension and hyperlipidemia, COPD and OP poisoning, and stroke and COPD. The HRs of the OP poisoning and non–OP poisoning cohort and the 95% CIs of AKI were estimated using the Cox model. The Kaplan–Meier method was used to estimate the cumulative incidence of AKI for the OP poisoning and non–OP poisoning cohorts, and the log-rank test was used to test the difference between the curves. All the statistical analyses were performed using SAS software (version 9.3 for Windows; SAS Institute, Cary, NC). A 2-tailed P < 0.05 was considered significant.

RESULTS

Table 1 displays the distributions of age, sex, and comorbidities of the 2 cohorts. Most patients were aged ≥50 years (57.1% in both cohorts) and men (69.8% in both cohorts). The median ages of the OP poisoning and non–OP poisoning cohorts were 53.7 and 53.3 years, respectively. The OP poisoning cohort and the non–OP poisoning cohort were well matched for comorbidities. The median duration of follow-up was 5.73 (95% CI 5.51–5.67) years in the OP poisoning cohort and 6.71 (95% CI 6.39–6.46) years in the non–OP poisoning cohort. The cumulative incidence of AKI was higher in the OP poisoning cohort than in the non–OP poisoning cohort (log-rank test P < 0.001) by the end of the follow-up (Fig. 2).

The incidence of AKI in the OP poisoning cohort was 4.85 per 1000 person-years, which was 1.39-fold higher than that in the non–OP poisoning cohort (3.47/1000 person-years), with an adjusted HR of 6.17 (95% CI 3.28–11.6) (Table 2). The incidence of AKI increased as age increased, in men more than women and among patients with comorbidity. In the multivariable model, the adjusted HR of AKI was 7.06-fold (95% CI 4.92–10.1) higher for patients aged ≥65 years, compared with patients aged <34 years, and 1.45-fold higher for men than for women (95% CI 1.26–1.67). Patients with diabetes, hypertension, hyperlipidemia, COPD, and CHF were also significantly associated with an increased risk of AKI.

The relative risk of AKI in the age-specific OP poisoning cohort compared with the non–OP poisoning cohort was higher for all age groups, except for the group aged 50 to 64 years (adjusted HR 9.65, 95% CI 4.75–19.6 for ages ≤34 years; adjusted HR 3.43, 95% CI 2.27–5.19 for ages 35–49 years; adjusted HR 1.43, 95% CI 1.08–1.89 for ages 65+ years, respectively) (Table 3). The adjusted HR of AKI in the sex-specific OP poisoning cohort and non–OP poisoning cohort was significant for both women and men. The risk of AKI was higher in the OP poisoning cohort than in the non–OP poisoning cohort for patients without comorbidity and with comorbidity. In the first year of follow-up, the OP poisoning cohort had a higher risk of AKI than that of the non–OP poisoning cohort (adjusted HR 104.9, 95% CI 23.8–462.0). Moreover, the risk of developing AKI in the OP poisoning cohort was significantly

| TABLE 1. Demographic characteristics and comorbidities in cohorts with and without organophosphate poisoning |
|---------------------------------------------------------------|
| **Organophosphate poisoning** | **No** | **Yes** | **P-value** |
|-------------------------------|---------|---------|------------|
| Age, year                     | N = 35691 | N = 8924 | 0.99       |
| ≤34                           | 5274 (14.8) | 1319 (14.8) |            |
| 35–49                         | 10025 (28.1) | 2507 (28.1) |            |
| 50–64                         | 10560 (29.6) | 2640 (29.6) |            |
| 65+                           | 9832 (27.5) | 2458 (27.5) |            |
| Median (95% CI)⁠| 53.3 (53.1–53.4) | 53.7 (53.2–53.9) | 0.18       |
| Sex                           | 0.99     |         |            |
| Female                        | 10,771 (30.2) | 2693 (30.2) |            |
| Male                          | 24,920 (69.8) | 6231 (69.8) |            |
| Comorbidity                   |         |         |            |
| Diabetes                      | 4383 (12.3) | 1097 (12.3) | 0.97       |
| Hypertension                  | 7369 (20.7) | 1843 (20.7) | 0.99       |
| Hyperlipidemia                | 2116 (5.93) | 530 (5.94) | 0.97       |
| COPD                          | 2363 (6.62) | 592 (6.63) | 0.96       |
| CAD                           | 3042 (8.52) | 761 (8.53) | 0.99       |
| Stroke                        | 2977 (8.34) | 745 (8.35) | 0.98       |

CAD = coronary artery disease, COPD = chronic obstructive pulmonary disease, CHF = congestive heart failure.

Chi-square Test.

⁠| Mann–Whitney U test. |
higher than that in the non–OP poisoning cohort with >1 year follow-up (adjusted HR 14.1, 95% CI 6.47–31.0).

Compared with patients without OP poisoning, patients with severe OP poisoning were 26.4-fold more likely to develop AKI (95% CI 12.5–55.8), followed by patients with less severe OP poisoning (adjusted HR 18.9, 95% CI 9.69–36.8). Compared with patients without OP poisoning, patients with OP poisoning and mechanical ventilation were 43.7-fold more likely to develop AKI (95% CI 16.2–118.3) (Table 4).

Compared with patients without OP and without other poisoning (eg, paraquat), patients with both OP and other poisoning (eg, paraquat) poisoning were 7.75-fold more likely to develop AKI (95% CI 3.55–16.9), followed by patients with OP poisoning only (adjusted HR 6.08, 95% CI 3.23–11.5) (Table 5). In addition, there was absence of renal tumor events (ICD-9-CM codes 189.0 and 189.1) in our study cohort during the following period.

**DISCUSSION**

Based on a literature review, this is the first population-based, retrospective, and longitudinal cohort study to show an association between OP poisoning and the subsequent risk of AKI development. The results indicate that patients with OP poisoning have a higher overall incidence and crude risk of developing AKI. After adjustment for possible confounders including age, sex, comorbidity, and interaction terms, the data remained statistically significant, indicating that patients with

| Variable | Event | PY | Rate | Crude HR (95% CI) | Adjusted HR (95% CI) |
|----------|-------|----|------|-----------------|---------------------|
| OP poisoning | No | 797 | 22,9376 | 3.47 | 1.00 | 1.00 |
| | Yes | 242 | 49,910 | 4.85 | 1.39 (1.21, 1.61)*** | 6.17 (3.28, 11.6)*** |
| Age, y | ≤34 | 48 | 46,026 | 1.04 | 1.00 | 1.00 |
| | 35–49 | 139 | 86,064 | 1.62 | 1.55 (1.12, 2.15)*** | 1.48 (1.05, 2.07)*** |
| | 50–64 | 304 | 85,122 | 3.57 | 3.45 (2.55, 4.68)*** | 2.75 (1.95, 3.86)*** |
| | 65+ | 548 | 62,073 | 8.83 | 8.67 (6.45, 11.7)*** | 7.06 (4.92, 10.1)*** |
| Sex | Female | 274 | 85,149 | 3.22 | 1.00 | 1.00 |
| | Male | 765 | 194,137 | 3.94 | 1.23 (1.07, 1.41)** | 1.45 (1.26, 1.67)*** |
| Comorbidity | Diabetes | No | 690 | 251,908 | 2.74 | 1.00 | 1.00 |
| | Yes | 349 | 27,378 | 12.8 | 4.71 (4.14, 5.37)*** | 9.65 (4.60, 20.2)*** |
| Hypertension | No | 616 | 233,382 | 2.64 | 1.00 | 1.00 |
| | Yes | 423 | 45,904 | 9.21 | 3.54 (3.13, 4.01)*** | 2.16 (1.79, 2.62)*** |
| Hyperlipidemia | No | 931 | 265,072 | 3.51 | 1.00 | 1.00 |
| | Yes | 108 | 14,214 | 9.21 | 3.25 (2.73, 3.85)*** | 2.04 (1.58, 2.64)*** |
| COPD | No | 855 | 265,039 | 3.34 | 1.00 | 1.00 |
| | Yes | 154 | 14,247 | 10.8 | 3.25 (2.73, 3.85)*** | 2.04 (1.58, 2.64)*** |
| CHF | No | 965 | 274,992 | 3.51 | 1.00 | 1.00 |
| | Yes | 74 | 4294 | 17.2 | 4.94 (3.90, 6.26)*** | 2.37 (1.83, 3.07)*** |
| CAD | No | 872 | 259,620 | 3.36 | 1.00 | 1.00 |
| | Yes | 167 | 19,667 | 8.49 | 2.54 (2.15, 2.99)*** | 1.07 (0.86, 1.33) |
| Stroke | No | 872 | 261,921 | 3.33 | 1.00 | 1.00 |
| | Yes | 167 | 17,365 | 9.62 | 2.91 (2.46, 3.43)*** | 1.70 (1.19, 2.43) |

AKI = acute kidney injury, CAD = coronary artery disease, CHF = congestive heart failure, CI = confidence interval, COPD = chronic obstructive pulmonary disease, OPD = organophosphate.

† Rate, incidence rate, per 10,000 person-years.

‡ Crude HR, relative HR.

§ Adjusted HR: multivariable analysis including age, sex, comorbidities of diabetes, hypertension, hyperlipidemia, COPD, CAD, and stroke, multiplicative interactions of age and OP poisoning; diabetes and OP poisoning, CAD and OP poisoning, stroke and OP poisoning, diabetes and age, hyperlipidemia and age, hypertension and diabetes, stroke and diabetes, hypertension and hyperlipidemia, hypertension and COPD, hypertension and stroke, hyperlipidemia and stroke, and COPD and CAD.

* P < 0.05

** P < 0.01

*** P < 0.001.
OP poisoning were at a 6.17-fold higher risk of developing AKI compared with the general population.

OP compounds are frequently used as pesticides, herbicides, and even chemical warfare agents, accounting for the greatest poison-related morbidity and mortality in agricultural societies. Dharmani and Jaga concluded from an epidemiologic review that suicidal and occupational poisonings were more prevalent in developing countries, whereas accidental poisonings were more prevalent in developed countries. In 1995, the Aum Shinrikyo Tokyo subway attack was one of the most lethal acts of chemical terrorism ever committed. The nerve agent sarin, a potent highly toxic OP compound was released by a religious cult and ultimately resulted in 12 deaths.

The clinical process of acute OP poisoning can be characterized by the following 3 phases: acute cholinergic crisis, intermediate syndrome (IMS), and OP-induced delayed neuropathy (OPIDN). Acute cholinergic crisis develops within a few minutes to hours after exposure to OP pesticides, with typical manifestations including nausea, vomiting, abdominal cramps, urinary incontinence, miosis, salivation, lacrimation, bronchorrhea, bradycardia, bronchospasm, hypotension, muscle fasciculation, paralysis, confusion, seizure, coma, and death. OPIDN occurs 2 to 5 weeks after acute OP exposure, with presentations of motor neuropathy, numbness, and weakness of the lower extremities, followed by progression to the proximal limbs and perhaps paraplegia, quadriplegia, or impotence, which may last for years. The specific toxidromes that occur between the end of a cholinergic crisis and the onset of OPIDN, referred to as the intermediate syndrome (IMS), are characterized by prominent weakness of the lower extremities, followed by progression to the proximal limbs. The specific toxidromes that occur between the end of a cholinergic crisis and the onset of OPIDN, referred to as the intermediate syndrome (IMS), are characterized by prominent weakness of the lower extremities, followed by progression to the proximal limbs. The specific toxidromes that occur between the end of a cholinergic crisis and the onset of OPIDN, referred to as the intermediate syndrome (IMS), are characterized by prominent weakness of the lower extremities, followed by progression to the proximal limbs.
Reportedly, renal impairment complicated by OP poisoning is rare or may be overlooked clinically but is more frequent and strongly related to late mortality in critically ill patients or patients with severe OP poisoning.\(^{16-18}\) In September 2004, the term AKI was proposed to reflect the entire spectrum of acute decline in renal function. AKI is currently defined by either change in serum creatinine or urine output,\(^{19}\) which affects 1% decline in renal function. AKI is currently defined by either term AKI was proposed to reflect the entire spectrum of acute kidney injury, CI = confidence interval, HR = hazard ratio, OP = organophosphate.

| Variables | N   | Event | Rate\(^1\) | Adjusted HR\(^1\) (95% CI) |
|-----------|-----|-------|------------|---------------------------|
| Non–OP poisoning | 35,691 | 797 | 3.47 | 1 (Reference) |
| OP poisoning severity\(^\ddagger\) | 7363 | 200 | 4.52 | 18.9 (9.69, 36.8)*** |
| Low severity | 1561 | 42 | 7.39 | 26.4 (12.5, 55.8)*** |
| Central venous pressure monitoring | 8907 | 242 | 4.85 | 18.9 (9.66, 36.9)*** |
| No | 17 | 0 | 0.00 | - |
| Yes | 8453 | 235 | 4.76 | 18.6 (9.51, 36.4)*** |
| Mechanical ventilation | 471 | 7 | 12.0 | 43.7 (16.2, 118.3)*** |

AKI = acute kidney injury, CI = confidence interval, HR = hazard ratio, OP = organophosphate.

\(^1\) Rate, incidence rate, per 1000 person-years.

\(^\ddagger\) Severity was identified according to hospitalization for OP poisoning within 3 days with respiratory failure (high) or without respiratory failure (low).

\(^{**}\) \(P < 0.001\).

### Table 5. Incidence and aHR of AKI Between Different Types of Poisoning

| Variables | N   | Event | Rate\(^1\) | Crude HR\(^1\) (95% CI) | Adjusted HR\(^6\) (95% CI) |
|-----------|-----|-------|------------|------------------------|---------------------------|
| None      | 35,658 | 795 | 3.47 | 1 (Reference) | 1 (Reference) |
| Other poisoning (eg, paraquat) | 33 | 2 | 9.38 | 2.68 (0.67, 10.8) | 2.83 (0.71, 11.3) |
| OP poisoning only | 8421 | 225 | 4.76 | 1.37 (1.18, 1.59)*** | 6.08 (3.23, 11.5)*** |
| Both      | 503 | 17 | 6.42 | 1.85 (1.14, 2.99)* | 7.75 (3.55, 16.9)*** |

aHR = adjusted hazard ratio, AKI = acute kidney injury, CI = confidence interval, HR = hazard ratio, OP = organophosphate.

\(^1\) Rate, incidence rate, per 10,000 person-years.

\(^*\) Crude HR, relative HR.

\(^\ddagger\) Adjusted HR: multivariable analysis including age, sex, comorbidities of diabetes, hypertension, hyperlipidemia, COPD, CAD, and stroke, multiplicative interactions of age and OP poisoning, diabetes and OP poisoning, CAD and OP poisoning, stroke and OP poisoning, diabetes and age, hyperlipidemia and age, hypertension and diabetes, stroke and diabetes, hypertension and hyperlipidemia, hypertension and COPD, hypertension and stroke, hyperlipidemia and stroke, and COPD and CAD.

\(^{**}\) \(P < 0.01\).

\(^{***}\) \(P < 0.001\).
acute renal failure and multiple organ dysfunction syndrome, suggesting that high intratubular OP concentrations and hypoxemia might be responsible for AKI. Similarly, Cavari et al. proposed that OP effects on the renal system could be due to direct parenchymal intoxication, secondary to hemodynamic instability, or seizure-induced rhabdomyolysis. In summary, we hypothesize that bradycardia, dehydration with hypoxemia, and hypotension that induced renal hyperperfusion, direct toxic effects on renal parenchyma and convolutions, endothelial cell damage, activation of immune and inflammatory responses, formation of free radicals, convulsive seizure, and muscular fasciculation–related rhabdomyolysis may all contribute to the decline of renal function after acute poisoning from OP pesticide. In addition, hemodilution induced by massive fluid resuscitation, which impairs the oxygen supply to the kidney may also play a role. Notably, OP effects are not confined to the acute stage. Our data revealed a significant increased risk of AKI after 1 year of follow up, indicating the possible presence of long-term effects. Moreover, the median follow-up time for AKI events in the OP poisoning cohort (5.73 years) was shorter than that in the non–OP poisoning cohort (6.71 years), suggesting that OP played a role in facilitating the development of AKI.

Bardin and Van Eeden developed the clinical severity grading system of OP poisoning and defined life-threatening poisoning as suicidal attempts, stupor, hypoxic respiratory distress, and abnormal chest roentgenogram. Because of the unavailability of certain history and clinical information from our claims dataset, including radiological and laboratory data, acute respiratory failure (ICD-9-CM code 518.81) diagnosed within the first 3 days of hospitalization was considered the indicator for distinguishing between the high- and low-severity groups and for calculating the relative risk of AKI for each group. Expectedly, the result exhibited a substantially higher risk of AKI in the high-severity group, with adequate statistical significance. Moreover, patients with OP poisoning, who required mechanical ventilation support during the first 3 days of hospitalization, exhibited a considerably higher risk of developing AKI than those without OP poisoning. Previous studies have proposed the harmful bidirectional interaction between acute lung injury and AKI in critically ill patients. We believe that the renal effects of acute lung injury and mechanical ventilation, termed “ventilator-induced kidney injury,” could play a role in the pathogenesis of AKI in patients with severe OP-poisoning.

Previous studies have shown that poisoning other than with OP compound (eg, paraquat) are strongly correlated with acute kidney damage. In our additional analysis, dual intoxication with OP and other types of poisoning exhibited a 7.75-fold higher risk of subsequent AKI development, whereas other poisoning alone failed to show a statistically significant renal effect. We suppose that it may be due to insufficient numbers of cases for data analysis (Table 5).

In our study, patients with newly developed AKI events since the index date and during the follow-up period till the end of 2011 were documented. Actually, it is hard to separate the events from acute effect (may have developed few minutes to hours after poisoning) from late effect (may have developed days to weeks after poisoning) in various clinical settings and disease severity. However, the follow-up time analysis (Table 3) showed the significant increased risk of AKI after a 1-year follow-up, might indicate the presence of long-term effect. In addition, the median follow-up time for AKI events were 5.73 years (OP cohort) and 6.71 years (non-OP cohort), which also suggested the possible existence of long-term effect that promoted the subsequent development of AKI.

LIMITATIONS

A major advantage of this study is the use of a large-scale claims database that covers >99% of the population in Taiwan. Although not originally designed for academic research, this database facilitated accurate and clear observations for each event occurrence and served as an appropriate representative of the population. In addition, disease definitions were based on ICD-9-CM codes, which were meticulously and repeatedly reviewed by physicians and medical reimbursement specialists throughout the hospital course; thus, most selection bias could be avoided. However, miscoding and misclassification may still exist. Next, the NHIRD lacks individual information regarding family history, socioeconomic background, cigarette smoking habits, body mass index, severity of comorbidities and laboratory data, which were considered highly associated with AKI development; hence, we could not adjust for them. Furthermore, in our study, the outcome measure depended upon hospitalization with a newly diagnosed AKI, which raises the problem that patients diagnosed in outpatients might be missed and led to an underestimation of the occurrence of AKI. However, we believe such bias could be omitted due to the highly developed health care facilities in Taiwan that most of the patients with suspicious or newly recognized AKI would be referred for hospitalization for further investigation. Moreover, factors influencing the severity of poisoning regarding the agent, route, amount, and duration of exposure could not be validated. Therefore, because the only 3 indicators we selected for severity grading were acute respiratory failure, central venous pressure monitoring, and mechanical ventilation, drawing a conclusion may be inadequate. Furthermore, an observational cohort study is unable to fully explain causal relationships. Finally, our study sampling was based on the population of Taiwan; thus, our results may not be applicable to other countries and regions. All of the aforementioned factors constitute the major limitations of our study.

CONCLUSION

In conclusion, our research revealed the possible association between OP poisoning and the subsequent development of AKI. Although the exact mechanism underlying this correlation has not yet been confirmed, we believe our results could be valuable for physicians and intensivists in managing acute OP poisoning. Further investigation is warranted to determine the exact mechanism of the OP effect on the urinary system, the existence of long-term effects, and whether antidote therapy (atropine and oximes) would be beneficial in preventing the development of AKI.

REFERENCES

1. Carey JL, Dunn C, Gaspari RJ. Central respiratory failure during acute organophosphate poisoning. Respir Physiol Neurobiol. 2013;189:403–410.
2. Iyer R, Iken B, Leon A. Developments in alternative treatments for organophosphate poisoning. Toxicol Lett. 2015;233:200–206.
3. Yang CC, Deng JF. Intermediate syndrome following organophosphate insecticide poisoning. J Chin Med Assoc. 2007;70:467–472.
4. Leibson T, Lifshitz M. Organophosphate and carbamate poisoning: review of the current literature and summary of clinical and laboratory experience in southern Israel. Isr Med Assoc J. 2008;10:767–770.
5. Weissmann-Brenner A, Friedman LM, David A, et al. Organophosphate poisoning: a multihospital survey. *Isr Med Assoc J.* 2002;4:573–576.

6. Paudyal BP. Organophosphorus poisoning. *JNMA J Nepal Med Assoc.* 2008;47:251–258.

7. Karakus A, Celik MM, Karcigol M, et al. Cases of organophosphate poisoning treated with high-dose of atropine in an intensive care unit and the novel treatment approaches. *Toxicol Ind Health.* 2014;30:421–425.

8. King AM, Aaron CK. Organophosphate and carbamate poisoning. *Emerg Med Clin North Am.* 2015;33:133–151.

9. Pakula AM, Skinner RA. Acute kidney injury in the critically ill patient: a current review of the literature. *J Intensive Care Medicine.* 2015[Epub ahead of print].

10. Dharmani C, Jaga K. Epidemiology of acute organophosphate poisoning in hospital emergency room patients. *Rev Environ Health.* 2005;20:215–232.

11. Tokuda Y, Kikuchi M, Takahashi O, et al. Prehospital management of sarin nerve gas terrorism in urban settings: 10 years of progress after the Tokyo subway sarin attack. *Resuscitation.* 2006;68:193–202.

12. Yanagisawa N, Morita H, Nakajima T. Sarin experiences in Japan: acute toxicity and long-term effects. *J Neurol Sci.* 2006;249:76–85.

13. Peter JV, Sudarsan TI, Moran JL. Clinical features of organophosphate poisoning: a review of different classification systems and approaches. *Indian J Crit Care Med.* 2014;18:735–745.

14. Karki P, Ansari JA, Bhandary S, et al. Cardiac and electrocardiographical manifestations of acute organophosphate poisoning. *Singapore Med J.* 2004;45:385–389.

15. Mishra A, Pandya HV, Dave N, et al. Multi-organ dysfunction syndrome with dual organophosphate pesticides poisoning. *Toxicol Int.* 2013;20:275–277.

16. Fazl MS, Mughal S, Memon AQ. Acute and late complications of organophosphate poisoning. *J Coll Physicians Surg Pak.* 2011;21:288–290.

17. Agostini M, Bianchin A. Acute renal failure from organophosphate poisoning: a case of success with haemofiltration. *Hum Exp Toxicol.* 2003;22:165–167.

18. Cavari Y, Lundau D, Sofer S, et al. Organophosphate poisoning-induced acute renal failure. *Pediatr Emerg Care.* 2013;29:646–647.

19. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care.* 2007;11:R31.

20. Talabani B, Zouwail S, Pyart RD, et al. Epidemiology and outcome of community-acquired acute kidney injury. *Nephrology (Carlton).* 2014;19:282–287.

21. Poncio L, Balbi AL, Rocha EP, et al. The long-term outcome after acute kidney injury: a narrative review. *J Bras Nefrol.* 2015;37:115–120.

22. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. *Nat Rev Nephrol.* 2014;10:193–207.

23. Srisawat N, Kellum JA. Acute kidney injury: definition, epidemiology, and outcome. *Curr Opin Crit Care.* 2011;17:548–555.

24. Liangos O, Wald R, O’Bell JW, et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. *Clin J Am Soc Nephrol.* 2006;1:43–51.

25. Peres LA, Wandeure V, Matsuo T. Predictors of acute kidney injury and mortality in an Intensive Care Unit. *J Bras Nefrol.* 2015;37:38–46.

26. Arefi M, Taghaddosinejad F, Salamaty P, et al. Renal failure prevalence in poisoned patients. *Nephrourol Mon.* 2014;6:e11910.

27. Gokel Y. Subarachnoid hemorrhage and rhabdomyolysis induced acute renal failure complicating organophosphate intoxication. *Ren Fail.* 2002;24:867–871.

28. van den Akker JP, Egal M, Groeneveld AB. Invasive mechanical ventilation as a risk factor for acute kidney injury in the critically ill: a systematic review and meta-analysis. *Crit Care.* 2013;17:R98.

29. Bardin PG, Van Eeden SF. Organophosphate poisoning: grading the severity and comparing treatment between atropine and glycopyrrolate. *Crit Care Med.* 1990;18:956–960.

30. Yardan T, Baydin A, Acar E, et al. The role of serum cholinesterase activity and S100B protein in the evaluation of organophosphate poisoning. *Hum Exp Toxicol.* 2013;32:1081–1088.

31. Koyner JL, Murray PT. Acute kidney injury: a narrative review. *Curr Opin Crit Care.* 2013;20:275–277.

32. Murray PT. The kidney in respiratory failure and mechanical ventilation. *Contrib Nephrol.* 2010;165:159–165.

33. Mohamed F, Endre Z, Jayamanne S, et al. Kidney damage biomarkers detect acute kidney injury but only functional markers predict mortality after paraquat ingestion. *Toxicol Lett.* 2015;237:140–150.

34. Mohamed F, Endre Z, Jayamanne S, et al. Mechanisms underlying early rapid increases in creatinine in paraquat poisoning. *PLoS One.* 2015;10:e0122357.

35. Pavan M. Acute kidney injury following paraquat poisoning in India. *Iran J Kidney Dis.* 2013;7:64–66.